GV20 Therapeutics

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
IGSF8Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
GV20-0251Phase 1/2Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma …
Est. primary completion 2026-12-15 · NCT05669430 · CT.gov ↗
What to watch
2027 (1)
July 2027 (1)
GV20-0251Phase 1/2Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma …
Est. primary completion 2027-07-16 · NCT07070518 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
GV20-0251Phase 2Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck …
Est. primary completion 2028-06-15 · NCT07623642 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.